Merck shares Phase 3 trial results for its HIV-1 regimen, doravirine/islatravir, showing safety and comparable efficacy to existing therapies.
Merck’s Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials
Where Today's News Shapes Tomorrow
